Vagally mediated syncope and functional bradyarrhythmia are autonomic-mediated conditions that can produce recurrent syncope, injury and in some cases the need for permanent pacemaker therapy. Standard treatments do not directly target the underlying vagal reflexes. Cardioneuroablation (CNA) is an interventional approach that aims to modify cardiac autonomic inputs to treat these syndromes, but its broader adoption has been limited by uncertainty about patient selection, objective procedural endpoints and durable clinical outcomes.
This report summarizes a single-center experience using a uniform, prospectively maintained protocol in which CNA was guided by physiologic testing to verify vagal responses before and after ablation.
The cohort comprised 95 consecutive patients treated at a single center by a single lead operator. Indications were vagally mediated syncope (n = 78) and functional bradyarrhythmia (n = 17). The series was conducted under a standardized protocol and outcomes were followed through one year.
Institutional oversight was provided: the study was approved by the Mayo Clinic Institutional Review Board and patients provided research authorization according to institutional requirements.
Procedures incorporated extracardiac vagal stimulation (ECVS) performed before and after ablation. ECVS was used to provoke and document vagally mediated sinus and atrioventricular (AV) nodal responses prior to therapy and to verify attenuation or abolition of those responses after CNA. The protocol therefore provided a physiology-guided procedural endpoint rather than relying solely on anatomical or surrogate markers.
The source reports that a dedicated vagal stimulation device related to some authors’ intellectual property was used in preclinical work and in a subset of human procedures. Relevant competing interests are disclosed elsewhere in this report.
Physiologic responses to ECVS and clinical outcomes through one year were reported:
Before ablation, ECVS provoked sinus pauses in 95.8% of patients and AV block in 91.6%.
After ablation, sinus pauses were abolished in every patient and residual AV block remained in 4.2% of patients.
One-year freedom from recurrent syncope was 93.8% and one-year freedom from bradyarrhythmia-related events was 94.1%.
Syncope burden decreased from a median of 2.7 episodes per year to none.
Disease-specific quality of life improved substantially; the change met statistical significance (P < 0.001).
Among patients with pre-existing pacemakers, median atrial pacing burden fell from 22% to 0% after CNA.
These outcomes indicate both physiologic effect on vagal reflexes (as demonstrated by ECVS) and associated clinical benefits across symptom frequency, quality of life and device pacing burden in this cohort.
Through one year of follow-up the authors report no strokes, deaths or myocardial infarctions in the cohort. The abstract does not report other specific procedural complications, length of stay, or additional safety event rates; those details were not reported in the source abstract.
Authors disclosed competing interests relevant to devices and neurocardiac modulation. Specifically, several authors are inventors on intellectual property for a dedicated vagal stimulation device that was used in preclinical studies and in a subset of human procedures. One author disclosed inventor status for devices and methods not used in this study and relationships with multiple device companies; the source states no funding or resources from those relationships were used for the reported study. The remaining authors declared no competing interests relevant to the manuscript.
Ethical oversight: the Mayo Clinic Institutional Review Board approved the study and patients provided required research authorization. The manuscript notes that all relevant ethical guidelines were followed and necessary approvals and participant consents were obtained.
In this single-center, single-operator cohort, physiology-guided cardioneuroablation with extracardiac vagal stimulation to document and confirm vagal reflex attenuation was associated with high rates of freedom from recurrent syncope and bradyarrhythmia-related events at one year, marked reduction in syncope episodes, significant improvement in disease-specific quality of life, and lower atrial pacing burden among device patients. The series also reported elimination of ECVS-provoked sinus pauses in all patients and a very low residual rate of AV block after ablation.
The authors emphasize that multicenter controlled studies are needed to confirm these findings and to address open questions about generalizability, optimal patient selection, procedural safety details and long-term durability beyond one year.